Source link : https://newshealth.biz/health-news/palopegteriparatide-benefits-sustained-in-adults-with-chronic-hypoparathyroidism/
(MedPage Today) — ORLANDO — Palopegteriparatide (Yorvipath) led to sustained improvements over 2 years in adults with chronic hypoparathyroidism, according to long-term phase III PaTHway trial results. By week 104, nearly all participants… Source link : https://www.medpagetoday.com/meetingcoverage/aace/115643 Author : Publish date : 2025-05-18 23:20:00 Copyright for syndicated content belongs to the linked Source.
The post Palopegteriparatide Benefits Sustained in Adults With Chronic Hypoparathyroidism first appeared on News Health.
—-
Author : News Health
Publish date : 2025-05-18 23:20:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8